Credit Industriel ET Commercial Sells 140,000 Shares of Alumis Inc. $ALMS

Credit Industriel ET Commercial lessened its holdings in shares of Alumis Inc. (NASDAQ:ALMS) by 36.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 247,002 shares of the company’s stock after selling 140,000 shares during the quarter. Credit Industriel ET Commercial owned approximately 0.24% of Alumis worth $986,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Alumis by 64.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company’s stock valued at $77,000 after purchasing an additional 4,926 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Alumis by 24.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 61,645 shares of the company’s stock valued at $378,000 after purchasing an additional 11,949 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Alumis during the first quarter valued at about $111,000. Rhumbline Advisers raised its stake in Alumis by 21.7% in the first quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock worth $102,000 after buying an additional 2,949 shares in the last quarter. Finally, Blair William & Co. IL purchased a new stake in Alumis in the second quarter worth about $200,000.

Insider Activity

In other Alumis news, major shareholder Foresite Capital Management Vi acquired 411,764 shares of the stock in a transaction that occurred on Thursday, January 8th. The shares were acquired at an average cost of $17.00 per share, with a total value of $6,999,988.00. Following the transaction, the insider owned 5,702,536 shares of the company’s stock, valued at $96,943,112. The trade was a 7.78% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Foresite Labs, Llc bought 411,764 shares of the business’s stock in a transaction on Thursday, January 8th. The shares were acquired at an average price of $17.00 per share, for a total transaction of $6,999,988.00. Following the completion of the purchase, the insider owned 5,702,536 shares in the company, valued at approximately $96,943,112. The trade was a 7.78% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 3,735,309 shares of company stock worth $44,543,340 over the last three months. 40.70% of the stock is currently owned by insiders.

Alumis Price Performance

Shares of NASDAQ:ALMS opened at $26.54 on Monday. The business has a fifty day moving average price of $18.74 and a 200-day moving average price of $9.84. The company has a market capitalization of $2.77 billion, a PE ratio of -6.55 and a beta of -2.13. Alumis Inc. has a 1-year low of $2.76 and a 1-year high of $28.29.

Alumis (NASDAQ:ALMS) last released its quarterly earnings data on Thursday, November 13th. The company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.14). The business had revenue of $2.07 million for the quarter, compared to analyst estimates of $3.14 million. On average, sell-side analysts anticipate that Alumis Inc. will post -8.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Chardan Capital assumed coverage on Alumis in a research report on Wednesday, January 21st. They issued a “buy” rating and a $37.00 target price for the company. Wall Street Zen raised Alumis from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Guggenheim increased their price objective on Alumis from $18.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. HC Wainwright reissued a “buy” rating and set a $40.00 price objective (up previously from $20.00) on shares of Alumis in a research report on Friday, January 9th. Finally, Morgan Stanley upped their target price on shares of Alumis from $22.00 to $33.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 7th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.50.

Alumis Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.